Goldman SachsGSPAST TOP PICKSep 05, 2017Stock price when the opinion was issued
As of Jul 21, 2026. Market Open.
Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.
Mergers are increasing, and banks like GS makes advisory fees from them. Also, the banks have been rallying since oil slumped, and will benefit further from rising interest rates, which appears will happen later this year. Plus, hyperscalers may need to keep borrowing money to keep competing with each other.
(A Top Pick June 9/17. Down 1.22%.) This is taking it on the chin a little as the 10-year treasury moved back down to under 2.1%, but that is the low point of 2017. These things are cyclical and eventually interest rates will pop up, and a company like this will follow suit. It will rebound once financial stocks start to move up again.